Intermune Inc (ITMN) 73.74 $ITMN
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015
PR Newswire - Fri Sep 05, 7:00AM CDT
InterMune, Inc. (Nasdaq: ITMN) today provided the following notice to the indenture trustee and holders of its outstanding 5.00% Convertible Senior Notes Due 2015:
Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.
Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Against InterMune, Inc. in Connection With Sale of Company to Roche Holding AG -- ITMN
GlobeNewswire - Wed Sep 03, 4:40PM CDT
The Law Offices of Vincent Wong notifies investors of claims of breaches of fiduciary duty against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune" in connection with the sale of the Company to Roche Holding AG. A complaint was filed in California state court.
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015
PR Newswire - Fri Sep 05, 7:00AM CDT
InterMune, Inc. (Nasdaq: ITMN) today provided the following notice to the indenture trustee and holders of its outstanding 5.00% Convertible Senior Notes Due 2015:
Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities. Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Against InterMune, Inc. in Connection With Sale of Company to Roche Holding AG -- ITMN
GlobeNewswire - Wed Sep 03, 4:40PM CDT
The Law Offices of Vincent Wong notifies investors of claims of breaches of fiduciary duty against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG. A complaint was filed in California state court. 
